Sonic Hedgehog Pathway as the Prognostic Marker in Patients with Extensive Stage Small Cell Lung Cancer

被引:22
|
作者
Lim, Seungtaek [1 ,2 ]
Lim, Sun Min [3 ]
Kim, Min-Ju [4 ]
Park, Shin Young [5 ]
Kim, Joo-Hang [3 ]
机构
[1] Yonsei Univ, Wonju Coll Med, Wonju Severance Christian Hosp, Dept Hernatooncol, Wonju, South Korea
[2] Konyang Univ, Myunggok Med Res Inst, Daejeon, South Korea
[3] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Div Med Oncol, 59 Yatap Ro, Seongnam 13496, South Korea
[4] Seegen Med Fdn, Seoul, South Korea
[5] Daejeon Son Hosp, Dept Pathol, Daejeon, South Korea
关键词
Small cell lung cancer; prognostic factors; hedgehog proteins; drug therapy; HUMAN HOMOLOG; CHEMOTHERAPY; COMBINATION; INHIBITION; CISPLATIN; GEFITINIB; GROWTH; TRIAL; PLUS;
D O I
10.3349/ymj.2019.60.10.898
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Sonic hedgehog (Shh) signaling pathway is known to play a crucial role in carcinogenesis in various malignancies, including lung cancer regarding tumorigenesis, angiogenesis, and cellular differentiation. The aim of this study was to investigate the value of components of Shh pathway as a prognostic marker in extensive stage small cell lung cancer (ES-SCLC) patients. Materials and Methods: We retrospectively analyzed data of 36 patients who were diagnosed with ES-SCLC between 2008 and 2012 at a single center. We performed immuo-histochemistry for glioma-associated oncogene homolog zinc finger protein 1 (Gli1), patched, Shh, and Ptch-mediated repression of smoothened (Smo) proteins using formalin-fixed, paraffin-embedded tissue derived from primary tumors. We then conducted survival analysis to evaluate the prognostic impact of these markers. Results: All 36 patients received platinum-based doublet chemotherapy. The median progression free survival and median overall survival were 6.9 months [95% confidence interval (CI), 6.5-7.3] and 11.7 months (95% CI, 9.1-14.3), respectively. The overall response rate was 84%. Of the 36 tissue specimens examined, over-expression of Gli1, Patched, Shh, and Smo was found in 12 (33.3%), five (13.9%), five (13.9%), and six (16.7%) cases, respectively. We found that high expression of Shh was associated with worse progression free survival (6.3 vs. 7.6 months, p=0.005) and overall survival (9.2 vs. 12.0 months, p=0.039) by both univariate and multivariate analyses, whereas other markers were not related to patient prognosis. Conclusion: A high proportion of small cell lung cancer tumors express proteins related to Shh pathway, and over-expression of Shh is correlated with poor prognosis.
引用
收藏
页码:898 / 904
页数:7
相关论文
共 50 条
  • [32] Effect of radiotherapy on the treatment of patients with extensive stage small cell lung cancer
    Wu, C.
    Wang, T.
    Wang, J.
    Qu, B.
    Wang, H.
    Hu, Y.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) : 8577 - 8585
  • [33] Bromodomain and hedgehog pathway targets in small cell lung cancer
    Kaur, Gurmeet
    Reinhart, Russell A.
    Monks, Anne
    Evans, David
    Morris, Joel
    Polley, Eric
    Teicher, Beverly A.
    CANCER LETTERS, 2016, 371 (02) : 225 - 239
  • [34] ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients
    Herreros-Pomares A.
    Doria P.
    Gallach S.
    Meri-Abad M.
    Guijarro R.
    Calabuig-Fariñas S.
    Camps C.
    Jantus-Lewintre E.
    Annals of Surgical Oncology, 2023, 30 (2) : 1238 - 1239
  • [35] Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
    Roviello, Giandomenico
    Generali, Daniele
    CURRENT CANCER DRUG TARGETS, 2016, 16 (03) : 209 - 214
  • [36] Prognostic factors for the survival of 66 cases with extensive stage-small cell lung cancer
    Heng Cao
    Yonggui Hong
    Shouran Zhao
    Nengchao Wang
    Fuyou Zhou
    Xiaodong Xie
    Oncology and Translational Medicine, 2016, 2 (01) : 12 - 15
  • [37] Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib
    Dongfang Chen
    Jianlin Xu
    Yizhuo Zhao
    Tianqing Chu
    Hua Zhong
    Baohui Han
    Runbo Zhong
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 401 - 406
  • [38] Mining prognostic factors of extensive-stage small-cell lung cancer patients using nomogram model
    Gao, Hongxiang
    Dang, Yazheng
    Qi, Tao
    Huang, Shigao
    Zhang, Xiaozhi
    MEDICINE, 2020, 99 (33) : E21798
  • [39] Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib
    Chen, Dongfang
    Xu, Jianlin
    Zhao, Yizhuo
    Chu, Tianqing
    Zhong, Hua
    Han, Baohui
    Zhong, Runbo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (02) : 401 - 406
  • [40] Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients
    Huang, Li-Ling
    Hu, Xing-Sheng
    Wang, Yan
    Li, Jun-Ling
    Wang, Hong-Yu
    Liu, Peng
    Xu, Jian-Ping
    He, Xiao-Hui
    Hao, Xue-Zhi
    Jiang, Pei-Di
    Liu, Yu-Tao
    Luo, Jian
    Zhou, Sheng-Yu
    Wang, Jin-Wan
    Yang, Jian-Liang
    Qin, Yan
    Yuan, Peng
    Lin, Lin
    Shi, Yuan-Kai
    THORACIC CANCER, 2021, 12 (13) : 1943 - 1951